Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Zidesamtinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvalent's Zidesamtinib NDA Accepted By FDA For Ros1+ NSCLC
    Nuvalent's Zidesamtinib NDA Accepted By FDA For Ros1+ NSCLC

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-announces-fda-acceptance-of-new-drug-application-for-zidesamtinib-for-the-treatment-of-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-302620883.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    Nuvalent To Present Patient-Reported Outcomes From Zidesamtinib
    Nuvalent To Present Patient-Reported Outcomes From Zidesamtinib

    05 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-patient-reported-outcomes-data-from-arros-1-trial-of-ros1-selective-inhibitor-zidesamtinib-at-2025-iaslc-asco-north-america-conference-on-lung-cancer-302604748.html

    PR NEWSWIRE
    05 Nov 2025
    Share Share
    Nuvalent's ARROS-1 Data on Zidesamtinib for ROS1-positive NSCLC
    Nuvalent's ARROS-1 Data on Zidesamtinib for ROS1-positive NSCLC

    13 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-pivotal-data-from-arros-1-clinical-trial-of-zidesamtinib-for-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-at-wclc-2025-presidential-symposium-302529250.html

    PR NEWSWIRE
    13 Aug 2025
    Share Share
    Nuvalent Publishes Study on Zidesamtinib as ROS1 Inhibitor
    Nuvalent Publishes Study on Zidesamtinib as ROS1 Inhibitor

    29 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-announces-publication-in-molecular-cancer-therapeutics-reinforcing-rational-molecular-design-of-zidesamtinib-as-a-novel-ros1-selective-inhibitor-302441619.html

    PR NEWSWIRE
    29 Apr 2025
    Share Share
    Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors
    Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/updated-data-for-nuvalents-alk-selective-inhibitor-nvl-655-and-ros1-selective-inhibitor-zidesamtinib-continue-to-support-potential-best-in-class-profiles-302241297.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024
    Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024

    16 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-updated-data-for-ros1-selective-inhibitor-zidesamtinib-and-alk-selective-inhibitor-nvl-655-at-the-esmo-congress-2024-302197499.html

    PR NEWSWIRE
    16 Jul 2024
    Share Share